Why is the ResMed share price climbing today?

ResMed shares are trading ex-dividend.

| More on:
A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ResMed shares push 1.40% higher to $28.25 
  • The company's shares are trading ex-dividend today 
  • ResMed is set to pay its latest quarterly dividend to eligible shareholders on 16 June 

The ResMed Inc (ASX: RMD) share price is heading north during early Wednesday morning.

At the time of writing, the sleep treatment focused medical device company's shares are up 1.40% to $28.25.

Why are ResMed shares edging higher today? 

Following the company's third quarter results released on 29 April, investors are eyeing ResMed shares as they go ex-dividend today.

While typically a company's shares travel lower on the ex-dividend date, this hasn't been the case this morning. This is because of the heavy losses ResMed has recorded in the past few weeks, hitting an 11-month low of $27.51 yesterday.

It appears that bargain hunters are swooping in to take advantage of the recent share price weakness.

What does this mean for ResMed shareholders?

For those eligible for ResMed's quarterly dividend, shareholders will receive a payment of US 4.2 cents per share on 16 June. The dividend is unfranked, which means investors will unfortunately miss out on the tax credits.

The latest dividend reflects a 7.69% increase when compared to the prior corresponding period (US 3.9 cents per share).

In case you were wondering, the company does not have a dividend reinvestment plan (DRP).

Are ResMed shares a buy now?

Following the company's financial scorecard, a couple of brokers weighed in on the ResMed share price.

The team at Goldman Sachs cut its 12-month price target by 6% to $33.70 for the healthcare company's shares. Its analysts believe that there is still more upside in ResMed shares despite missing its performance targets recently.

Based on the current share price, this implies an upside of about 19% for investors.

Furthermore, Macquarie also slashed its rating on ResMed shares by 2.7% to $36.50 a pop. This also implies an upside of around 29% from where the company trades today.

ResMed share price summary

Over the past 12 months, ResMed shares have gained 14% on the back of positive investor sentiment. On the other hand, the S&P/ASX 200 Index (ASX: XJO) has fallen by 1% over the same timeframe.

ResMed shares reached a 52-week high of $40.49 in August, before backtracking amid inflationary movements and soaring living costs.

Based on today's price, ResMed commands a market capitalisation of roughly $11.41 billion and has a trailing dividend yield of 0.56%.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »